---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-061505"
form_type: "8-K"
ticker: "AMLX"
cik: "0001658551"
company_name: "Amylyx Pharmaceuticals, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T06:53:52.575772+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Amylyx reports Q3 product revenue $102.7M, net income $20.9M, PHOENIX topline Q2 2024

## Summary
- Net product revenue $102.7M (Q3) vs $98.2M (Q2 2023) and $0.3M (Q3 2022).
- Net income $20.9M ($0.30 diluted EPS) compared to net loss $53.8M in Q3 2022.
- Cash, equivalents and short-term investments $355.0M at Sept 30, 2023.
- Post hoc analysis: median overall survival 10.4 months longer with AMX0035 vs historical control.
- CHMP reaffirmed negative EU opinion; final decision end 2023. PHOENIX Phase 3 topline expected Q2 2024.

## SEC filing metadata
- accession: 0000950170-23-061505
- form_type: 8-K
- ticker: AMLX
- cik: 0001658551
- company_name: Amylyx Pharmaceuticals, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658551/000095017023061505/0000950170-23-061505-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658551/000095017023061505/amlx-20231109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-061505
- JSON: https://secwatch.observer/filing/0000950170-23-061505.json
- Plain text: https://secwatch.observer/filing/0000950170-23-061505.txt

## Key facts
- Earnings Releases
  Amylyx Pharmaceuticals, Inc. reported the fiscal quarter ended September 30, 2023 results: revenue $102.7 million, net income $20.9 million, EPS $0.30 on a fully diluted per share basis.
  - Period: the fiscal quarter ended September 30, 2023
  - Revenue: $102.7 million
  - Net income: $20.9 million
  - EPS: $0.30 on a fully diluted per share basis
  - Result: reported results
  source text: in such filing. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Amylyx Pharmaceuticals Reports Third Quarter 2023 Financial Results ˗ Third quarter 2023 product revenue of $102.7 million; bringing total product revenue to $272.3 million in the first three full quarters of U.S. launch ˗ Strong financial position supported by $20.9 million of net income during the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1658551/000095017023061505/0000950170-23-061505-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.